Tag: Annual Financial Results

Business CRO Healthcare & Pharmaceuticals News

Charles River Laboratories 2025 Earnings: Full-Year Revenue of $4.02 Billion with Strategic Growth Initiatives

Charles_River_Laboratories news and statistics

Charles River Laboratories reported 2025 full-year revenue of $4.02 billion, down 0.9% from 2024, with non-GAAP earnings per share of $10.28. The company faced headwinds in its Discovery and Safety Assessment and Manufacturing segments, though Q4 bookings showed substantial improvement, signaling stabilization in the biopharmaceutical market. CEO James C. Foster stated the company is “cautiously optimistic” about 2026, expecting organic revenue growth in the second half of the year. For 2026, management projects non-GAAP EPS of $10.70-$11.20, representing 4-9% growth, driven by cost savings from restructuring initiatives and a lower tax rate. Strategic acquisitions and operational efficiency improvements remain core to the company’s growth strategy.

Business News Supply Chain

Avantor Navigates “Year of Transition” with New Revival Program; Reports Full Year 2025 Results

avantor

Avantor, Inc. concludes fiscal 2025 with a strategic pivot. While facing a GAAP net loss due to significant impairment charges, CEO Emmanuel Ligner introduces the “Revival” initiative a comprehensive plan to modernize e-commerce, relaunch the VWR brand, and optimize go-to-market strategies for a “transition year” in 2026.

Business Healthcare & Pharmaceuticals News

AstraZeneca Delivers Robust 2025 Results as $58.7B Revenue as “Blockbuster” Portfolio Expands to 16 Medicines

AstraZeneca

AstraZeneca (AZN) capped off 2025 with a powerhouse performance, reaching $58.74 billion in total revenue and expanding its portfolio to 16 blockbuster drugs. With 100+ Phase III trials ongoing, CEO Pascal Soriot reaffirmed the company’s path to an $80 billion revenue target by 2030.

Business Healthcare & Pharmaceuticals

IQVIA Outpaces Expectations in 2025, Doubles Down on Healthcare-Grade AI Strategy for 2026

iqvia news

Following the release of its IQVIA 2025 earnings, the life sciences leader reported a record-breaking $32.7 billion backlog and a double-digit revenue surge in the fourth quarter, outperforming Wall Street expectations. As the company transitions into 2026, it is doubling down on a specialized Healthcare-grade AI strategy—anchored by its proprietary Med-R1 reasoning model and strategic cloud partnerships with NVIDIA and AWS—to safeguard its core business against industry-wide disruption.

Business Anti-obesity Drugs Diabetes News

Eli Lilly Released Q4 and 2025 Results; Projects $80B+ Revenue for 2026 as Oral Weight-Loss Drug Orforglipron Nears Approval

Eli Lilly and Company

Eli Lilly (LLY) shattered Q4 2025 expectations with $19.3 billion in revenue, marking a 43% year-over-year increase. Driven by the explosive demand for weight-loss treatments Mounjaro and Zepbound, the pharmaceutical giant issued a confident 2026 revenue guidance of $80B–$83B, signaling continued dominance in the metabolic health market.

Business News

Roche Reports Strong 2025 Financial Performance with 7% Sales Growth and Major Pipeline Breakthroughs

Roche

Roche has announced robust 2025 results, reporting a 7% increase in Group sales (CER) and a massive 58% jump in IFRS net income. With 12 positive late-stage clinical readouts—including the promising obesity candidate CT-388—and a bullish 2026 forecast, the Swiss healthcare giant proves its resilience despite significant currency headwinds.

Business Healthcare & Pharmaceuticals News

Samsung Biologics Reports Q4 Results, Achieves Record KRW 4.5 Trillion Revenue in 2025, Sets Sights on U.S. Expansion

samsung biologics

Samsung Biologics (KRX: 207940.KS), a world-leading contract development and manufacturing organization (CDMO), has reported record-breaking financial results for the fourth quarter and full fiscal year [Read More…]

News Business Healthcare & Pharmaceuticals

Abbott Signals Accelerating Growth for 2026 Following Strong Q4 and 2025 Performance

abbott

Abbott concludes 2025 with double-digit earnings growth and a powerful surge in Medical Device sales. With a new 2026 organic growth forecast of 6.5%–7.5% and a major entry into cancer diagnostics via the Exact Sciences acquisition, the healthcare leader signals a year of accelerated expansion ahead.

Business Healthcare & Pharmaceuticals News

Johnson & Johnson Reports Record Q4 and 2025 Results; Targets $100 Billion Milestone for 2026

JohnsonAndJohnson

ohnson & Johnson has concluded a ‘catapult year’ with $94.2 billion in revenue, driven by a surge in oncology sales and strategic MedTech innovations. As the healthcare giant prepares to spin off its orthopaedics business, it sets its sights on becoming the first healthcare company to surpass the $100 billion annual revenue milestone in 2026.